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MicePandemic inﬂuenza viral infections have been associated with viral pneumonia. Chimeric inﬂuenza viruses
with the hemagglutinin segment of the 1918, 1957, 1968, or 2009 pandemic inﬂuenza viruses in the context
of a seasonal H1N1 inﬂuenza genome were constructed to analyze the role of hemagglutinin (HA) in
pathogenesis and cell tropism in a mouse model. We also explored whether there was an association between
the ability of lung surfactant protein D (SP-D) to bind to the HA and the ability of the corresponding chimeric
virus to infect bronchiolar and alveolar epithelial cells of the lower respiratory tract. Viruses expressing the
hemagglutinin of pandemic viruses were associated with signiﬁcant pathology in the lower respiratory tract,
including acute inﬂammation, and showed low binding activity for SP-D. In contrast, the virus expressing the
HA of a seasonal inﬂuenza strain induced only mild disease with little lung pathology in infected mice and
exhibited strong in vitro binding to SP-D.iseases, NIAID, NIH, 33 North
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Inﬂuenza A virus (IAV) in humans primarily causes an acute
respiratory infection with inﬂammation of the upper respiratory tree
and trachea. While in most cases pneumonic involvement is not
clinically prominent, virus can be recovered from both the upper and
lower respiratory tract. Under certain still poorly understood
circumstances, infection can lead to the development of viral
pneumonia, characterized by injury to the gas exchange tissue,
often with severe clinical consequences (Taubenberger and Morens,
2008). Severe disease is more often associated with the emergence of
novel inﬂuenza viruses that cause pandemics (Simonsen et al., 1998;
Wright, Neumann, and Kawaoka, 2007). In the last 100 years,
inﬂuenza pandemics occurred in 1918, 1957, 1968, and 2009, and
were associated with varying levels of morbidity and excess mortality
(Morens, Taubenberger, and Fauci, 2009). Postmortem examinations
from patients dying during these pandemics have revealed strikingsimilarities in the spectrum of pathological changes in the lower
respiratory tract (Gill et al., 2010; Kuiken and Taubenberger, 2008;
Morens, Taubenberger, and Fauci, 2008; Mulder and Hers, 1972;
Taubenberger and Morens, 2008). One key pathological feature in
fatal cases, also prominent in postmortem examination of lung
sections from victims of the 2009 H1N1 pandemic, was severe
lower respiratory tract pathological changes associated with wide-
spread infection of bronchiolar and alveolar epithelial cells and
alveolar macrophages (Gill et al., 2010).
IAV hemagglutinin (HA) and neuraminidase (NA) are viral surface
glycoproteins that mediate receptor binding and virion release from
the host cell, respectively. HA recognizes sialic acid bound to
underlying sugars on host cell glycoproteins. IAV adapted to birds
have an HA receptor binding speciﬁcity for SA-α2,3-galactose, while
HA from IAV adapted to humans typically have higher speciﬁcity for
SA-α2,6-galactose (Matrosovich et al., 2000; Matrosovich et al., 1997;
Rogers and Paulson, 1983). This binding preference is believed to be an
important determinant of IAV cell tropism within a host. Lectin
histochemistry studies have demonstrated that the respiratory tract of
humans bears both α2-6 and α2-3 linked sialic acids but that α2-3
sialic acids are more prevalent in the lower respiratory tract (Nicholls
et al., 2007; Shinya et al., 2006). Although pandemic viruses display
preference for α2-6 linked sialic acids, autopsy reports indicate that
they still can cause severe alveolitis, a consequence of infection of the
lower respiratory tract. Moreover, in a recent study, Qi et al. (2009)
427L. Qi et al. / Virology 412 (2011) 426–434demonstrated that IAV expressing the 1918 HA possessing either an
SA-α2,6-galactose speciﬁcity, an SA-α2,3-galactose speciﬁcity, or a
mixed SA-α2,6-galactose/SA-α2,3-galactose speciﬁcity were lethal to
mice, with similar pathology and cellular tropism. This suggests that
IAV respiratory tract tropism both in humans and mice must be
inﬂuenced by other features of HA proteins than their SA binding
speciﬁcity.
It has been reported that mannose-containing glycans on the viral
HA and NA proteins can be recognized by components of the innate
immune system, such as, for instance, C-type lectins of the collectin
family, including surface surfactant protein D (SP-D) (Crouch, 2000;
Hartshorn, 2010; Hartshorn et al., 1994; Hartshorn et al., 2008;
Hartshorn et al., 1997; Hartshorn et al., 2007; Hartshorn et al., 2000;
LeVine et al., 2001; Reading et al., 1997). SP-D is constitutively
expressed by alveolar type II pneumocytes and non-ciliated bronchi-
olar (Clara) cells in the lower respiratory tractwhere it is considered to
represent a counterpart of IgA, thereby playing a key role in the innate
immune system (Crouch, 2000; Litvack et al., 2010). SP-D, together
with other proteins, is believed to establish a ﬁrst line of defense
against both bacterial and viral pathogens by binding to carbohydrate
moieties on the pathogen surface (Hartshorn, 2010). Most interest-
ingly, SP-D has previously been shown to bind to carbohydrate
residues on some inﬂuenza A viruses, thereby inhibiting their HA
binding activity, causing viral aggregation (Hartshorn et al., 2008), and
eventually leading to pathogen inactivation through activation of
neutrophil and macrophage activity (Crouch, 2000; Hartshorn et al.,
1994). Furthermore, SP-D may enhance viral clearance by binding to
the carbohydrate side chains of IAV, blocking access of the HA receptor
binding domain to cell surface receptors, and thus, interfering with
virus internalization by host cells (Hartshorn et al., 2008). The ability of
SP-D to bind the glycan component of HA protein has been shown to
require high mannose type II glycans.
Previous analysis of the glycosylation patterns of the HA proteins
from representative viruses of the 1957 H2N2 pandemic
(A/Singapore/1/1957), the 1968 H3N2 pandemic (A/Aichi/1/1968),
and a close relative of the pandemic 1918 inﬂuenza virus (A/Swine/
Iowa/1931) observed an absence of type II glycans (Hartshorn et al.,
2008; Schwarz and Klenk, 1981; Vigerust et al., 2007).While the exact
glycosylation pattern of the 1918 and 2009 pandemic IAV HA proteins
has yet to be determined, the deduced potential glycosylation pattern
based on amino acid sequence predicts a lack of type II glycans (Reid
et al., 1999; Stevens et al., 2004; Wei et al., 2010), and we
hypothesized that the 2009 pandemic HA and the HA proteins of
other pandemic IAV would have low binding activity with SP-D that
would likely be associated with an enhanced ability of these viruses to
invade deeper into the lower lung and infect alveolar lining cells.
In the present study,we tested this hypothesis and show that theHA
proteins from pandemic inﬂuenza viruses show low SP-D binding in
vitro and that chimeric viruses expressing the 1918, 1957, 1968, or 2009
pandemic virusHA inducedmore severe disease inmice as compared toTable 1
Properties of viruses tested.
Virus Subtype MDCK titer
(PFU/ml log10)
1918-HA:NY312 H1N1 7.2
1957-HA:NY312 H2N1 6.7
1968-HA:NY312 H3N1 6.5
2009-HA:NY312 H1N1 6.1
NY312 H1N1 7.0
1918-HA,NA:NY312 H1N1 6.8
1957-HA,NA:NY312 H2N2 6.5
1968-HA,NA:NY312 H3N2 6.6
a Mass of human SP-D protein required to inhibit agglutination of turkey RBCs.
b Determined by plaque reduction assay.seasonal IAVwith increased SP-D binding activity. In addition, we show
that enhanced alveolar and bronchiolar epithelial cell tropism is
associated with severe lower lung pathology and more signiﬁcant
activation of host inﬂammatory responses. Our results demonstrate that
low SP-D binding is a common feature of the HA proteins from the past
four inﬂuenza pandemics and that this is also associated with increased
morbidity, mortality, lung pathology, and inﬂammatory responses in
mice infected with an otherwise isogenic virus.
Results
Rescue of chimeric viruses containing the HA gene of pandemic IAVs
Using reverse genetics, a series of isogenic chimeric 1:7 inﬂuenza
viruses that contained the same 7 genomic segments derived from
A/New York/312/2001 (H1N1) [NY312], but different HA segments
were constructed. The latter encoded the HA gene of the 1918, 1957,
1968, or 2009 pandemic IAV, termed 1918-HA, 1957-HA, 1968-HA, or
2009-HA, respectively. The parental NY312 virus was also rescued. All
rescued 1:7 chimeric viruses replicated to titers of 106–107 PFU/ml in
cell culture (Table 1). To address if the HA/NA mismatch of the HA
gene from H2 (1957) and H3 (1968) viruses on the NY312 H1N1
background could inﬂuence replication of the chimeric viruses, we
also tested the 1918-HA, the 1957-HA, and the 1968-HA chimeric
viruses in the context of their cognate NA by rescuing 2:6 viruses
containing 6 NY312 gene segments and the HA and NA gene segments
of each of the pandemic viruses and measuring growth in MDCK cells
in vitro and their pathogenicity in vivo. These studies demonstrated
that the properties of the 1:7 HA and 2:6 HA+NA expressing chimeric
viruses tested in this study were very similar (Table 1). Similarly, the
properties of the 2009-HA virus were similar to the wild-type
A/Mexico/4108/09 (H1N1) virus (data not shown).
Morbidity and mortality of pandemic HA expressing isogenic
viruses in mice
To test whether the isogenic chimeric viruses expressing seasonal
or pandemic HA could cause differential disease and pathology in
mice, groups of ﬁve 8–10 week old BALB/c mice were intranasally
inoculatedwith each virus (Table 1) at a dose of 2×105 PFU. As shown
in Fig. 1A, mice infected with the NY312 parental virus showed only
very little weight loss during the ﬁrst three days post infection.
Whereas there was an average weight loss of about 10% in these mice
by day 4 p.i., all mice eventually recovered and none of the animals
died. In contrast, mice inoculated with the four pandemic HA
expressing chimeric viruses all exhibited rapid and signiﬁcant weight
loss beginning from day 1 post-infection (dpi) reaching a nadir at
3–4 dpi (Fig. 1A). Even though peak weight loss in mice infected with
1957-HA and 1968-HA was similar to the peak weight loss observed
with mice infected with NY312, by 4 dpi, mice infected with 1957-HASurfactant D protein (SP-D)
binding assays
MLD50 (PFU/ml log10)
HAIa IC50b
N2 μg N120 ng 5.25
N2 μg N120 ng 5.54
N2 μg N120 ng 5.41
N2 μg N120 ng N5.6
62.5 ng 7 ng N5.7
N2 μg N120 ng 3.8
N2 μg N120 ng 5.04
N2 μg N120 ng 5.45
Fig. 1. Weight loss and survival of mice infected with wild-type inﬂuenza viruses and
chimeric inﬂuenza viruses expressing the HA genes of different inﬂuenza viruses. (A)
Representative weight loss of mice infected with rescued inﬂuenza viruses. Eight-to-
ten-week-old female BALB/c mice were intranasally inoculated with 2×105 PFU of the
indicated viruses and weighed daily (n=5mice per virus per group). *Note that by day
4 post infection, one animal each infected with 1957-HA, 1968-HA, and 2009-HA had
died. ***Note that by day 6 post infection, 3 animals infected with 1918-HA had died.
(B) Kaplan–Meier survival curve of 8-to-10-week-old female BALB/c mice intranasally
inoculated with 2×105 PFU of the indicated viruses (n=20 mice per virus group,
except 1918-HA virus which had n=25).
Fig. 2. Lung pathology induced with different inﬂuenza A viruses. Pathology and
immunohistochemistry of inﬂuenza A virus-infected mouse lung tissue. Photomicro-
graphs of hematoxylin-and-eosin-stained tissue sections (A, C, E, G, I, K) and
immunohistochemically-stained sections (B, D, F, H, J, L) to detect inﬂuenza viral
antigen frommice infected with isogenic viruses expressing different HAs at 4 dpi. Viral
antigen is stained red-brown on a hematoxylin-stained background. The 1918-HA virus
(A, B) induced a moderate-severe alveolitis and bronchiolitis with viral antigen in both
bronchiolar epithelial and alveolar lining cells. The 1957-HA virus (C, D), the 1968-HA
virus (E, F), and the 2009-HA virus (G, H) induced similar pathologic changes with
mild-moderate alveolitis and bronchiolitis with viral antigen in both bronchiolar and
alveolar lining cells. The NY312 virus (I, J,K, H) induced no pathologic changes but did
show viral antigen staining in tracheobronchial and bronchiolar epithelial cells and
occasional alveolar macrophages [original magniﬁcations ×100].
428 L. Qi et al. / Virology 412 (2011) 426–434and 1968-HA each exhibited 20% mortality, which was statistically
signiﬁcant compared to NY312 (n=20; P=0.002). Similarly, the
2009-HA virus infected mice displayed peak weight loss comparable
to NY312 but exhibited 10% mortality, which did not reach statistical
signiﬁcance (n=20; P=0.273) (Fig. 1B). Interestingly, mice infected
with 1918-HA virus continued to lose weight until 6 dpi with an
Fig. 3. Pathology and immunohistochemistry of inﬂuenza A virus-infected mouse lung
tissue. Photomicrographs of hematoxylin-and-eosin-stained tissue sections and
immunohistochemically-stained sections to detect inﬂuenza viral antigen from mice
infected with isogenic viruses expressing different HAs at 4 dpi. Viral antigen is stained
red-brown on a hematoxylin-stained background. (A–C) 1918-HA virus induced an
alveolitis with a mixed cellular inﬂammatory inﬁltrate including numerous neutrophils
(arrowheads), lymphocytes, and macrophages (arrows). Viral antigen was detected in
alveolar macrophages (B, arrows) and alveolar lining cells (C, arrows). Viruses
expressing the 1957 (D–F), 1968 (G–I), or 2009 (J–L) pandemic HAs induced similar
pulmonary pathologic changes, consisting of an alveolitis with a mixed cellular
inﬂammatory inﬁltrate including numerous macrophages (arrows). Viral antigen was
detected in alveolar macrophages (E, H, K, arrows) and alveolar lining cells (F, I, L,
arrows). The NY312 (P–R) virus induced little appreciable pulmonary pathologic
changes, with no alveolitis (M, P). The lungs of NY312 virus-infected mice showed
occasional viral antigen positive alveolar macrophages (N, arrows) but no alveolar
lining cell staining (O) [original magniﬁcations ×1000].
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characterize further the virulence of the different viruses, the mouse
50% lethal dose (MLD50) of each of the pandemic HA expressing
viruses was determined where possible (Table 1). However, we were
unable to obtain a stock of 2009-HA with sufﬁciently high titer to
calculate a mouse LD50 for this virus (MLD50, N5.6). The calculated
MLD50 for the 1918-HA, 1957-HA, and 1968-HA viruses ranged
between 5.25 and 5.54 log10 PFU using the method of Reed and
Muench (1938).Evaluation of mouse lung pathology
To evaluate mouse lung pathology, 2 mice each infected with the
various viruses were sacriﬁced at 1, 2, 3, and 4 dpi and lung sections
were subjected to histopathological examination and immunohisto-
chemistry (IHC) for IAV antigen. Pathological changes were scored on
a severity scale from 0 (no signiﬁcant changes) to 4+ (severe). In
lungs of mice infected with the 1918-HA, 1957-HA, 1968-HA, and
2009-HA viruses, viral antigen was found as early as 1 dpi throughout
the entire lung (data not shown) and until the last time point
analyzed (4 dpi; Figs. 2 and 3). Intriguingly, however, in lungs of mice
infected with the seasonal NY312 virus, detection of viral antigen was
restricted to the large airways and the bronchiolar epithelium
throughout the observation period (Figs. 2 and 3, and data not
shown). Mice inoculated with the 1918-HA virus developed promi-
nent histopathologic changes at 3 and 4 dpi. Lung sections showed a
multifocal moderate-to-severe bronchiolitis, including focal necrotiz-
ing changes, and multifocal alveolitis, with a neutrophil-predominant
inﬂammatory inﬁltrate (pathological score of 3+) (Figs. 2A and 3A).
Inﬂuenza viral antigen was detected in the bronchiolar epithelium
(Fig. 2B), alveolar macrophages, and alveolar lining cells (Fig. 3B
and C). Mice inoculated with the 1957-HA (Figs. 2C and 3D), 1968-HA
(Figs. 2E and 3G), and 2009-HA (Figs. 2G and 3J) viruses showed
similar histopathologic changes beginning at 3 dpi. Lung sections
showed a multifocal mild-to-moderate bronchiolitis and alveolitis
pattern (pathological score of 2+ in each case). The inﬂammatory
inﬁltrates were predominantly lymphocytic and histiocytic with very
few granulocytes. Inﬂuenza viral antigen was detected in the
bronchiolar epithelium (Fig. 2D, F, and H), alveolar macrophages,
and alveolar lining cells (Fig. 3E, F, H, I, K, and L). In comparison, the
parental NY312 (Figs. 2I and K and 3M) virus showed little-to-no
pathologic changes at 4 dpi (pathological score of 0). Inﬂuenza viral
antigen was detected in the bronchiolar epithelium and tracheobron-
chial airway epithelium of the NY312 inoculated mice (Fig. 2J and L),
in rare alveolar macrophages (Fig. 3N), but not in alveolar lining cells
(Fig. 3N and O). The histopathologic changes outlined above for the
1:7 chimeric viruses were very similar to those observed with the 2:6
chimeric viruses (data not shown). The 2:6 1918-HA+NA virus
induced bronchiolitis and alveolitis, with a neutrophil-predominant
inﬂammatory inﬁltrate (score of 3+) (Qi et al., 2009). The 1957 and
1968 chimeric 2:6 pandemic HA+NA viruses also induced histo-
pathologic changes (score of 2+) similar to the cognate 1:7 HA
viruses described above.
Determination of cytokine and chemokine expression in lungs
of infected mice
The severity of inﬂuenza that induced disease in experimental
animals correlates well with the ability of virulent virus strains to
induce a robust expression of proinﬂammatory cytokines (Kobasa
et al., 2004; Peiris et al., 2009). Moreover, there is a strong association
between cytokine levels and the severity of clinical symptoms in
infected people (Deng et al., 2008; Yuen and Wong, 2005). Further-
more, the pathological studies outlined above demonstrated a select
tropismof viruseswithpandemic IAVHA for bronchiolar epithelial and
type II alveolar lining cells that was associatedwithmore severe lower
lung pathology. Because infected type II alveolar cells have also been
shown to play an important role in activation of innate immune
responses through increased expression of chemokines and cytokines
(Wang et al., 2009), we compared levels of cytokines/chemokines in
lungs of mice infected with the seasonal and pandemic HA expressing
viruses at 1–5 dpi (Fig. 4 and data not shown). Notably, among the
various chemokines and cytokines analyzed, only expression levels of
chemokines CCL2 (MCP-1) and colony-stimulating-factor-3 (CSF3)
displayed apparent differences between mice infected with NY312
versus mice infected with chimeric pandemic HA viruses (Fig. 4).
Fig. 4. Expression of CCL2 (MCP-1) and CSF3 (G-CSF) in lungs of mice infected with chimeric inﬂuenza viruses expressing the HA genes of different inﬂuenza viruses. Cytokine and
chemokine protein concentrations were determined frommouse lung homogenates as described in the methods from infected animals at indicated days post infection (note that no
samples were available for 2009-HA at day 5 post infection); (A) CCL2 (MCP-1) (B) CSF3 (G-CSF). Mean protein concentrations are shown in pg/g±SD. See key for different viruses.
Fig. 5. Lung titers in mice infected with wild-type inﬂuenza viruses and chimeric
inﬂuenza viruses expressing the HA genes of different inﬂuenza viruses. Virus titers in
the lungs of infected BALB/c mice (n=3) at days 1, 3, 4, and 6 post infection, plotted as
plaque-forming unit per gram (log10) of lung tissue as determined by plaque assay. ND
indicates not done; BD, below the limit of detection of the assay.
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difference in CCL2 and CSF3 expression levels between mice infected
with 1918-HA and NY312 viruses (P=b0.001), 1968-HA and NY312
viruses (P=b0.001), and 2009-HA and NY312 viruses (P=b0.001)
over the time course of the experiment. Moreover, there also was a
statistically signiﬁcant difference in CSF3 expression levels between
1957-HA and NY312 infected mice (P=b0.001) while the difference
in CCL2 expression levels between 1957-HA and NY312 infected mice
did not reach statistical signiﬁcance (P=0.062). Intriguingly, except
for 1 dpi, CCL2 and CSF3 expression levels were signiﬁcantly higher in
1918-HA infected lungs at all other time points as compared to the
other viruses. Indeed, 2-way ANOVA analysis also revealed statistically
signiﬁcant differences in CSF3 and CCL2 expression levels between
mice infected with 1918-HA and 1968-HA, 1957-HA and 2009-HA,
respectively (P=b0.001). Of note, CCL2 and CSF3 expression levels in
NY312 infected lungs also differed signiﬁcantly from lungs of mock-
infected mice (P=b0.001). Mice infected with 1918-HA virus also
showed higher expression levels of the chemokine CXCL1 (KC) and
chemokines IL-6 and TNFα were observed when compared to NY312
(2-way ANOVA; data not shown).
Determination of viral replication in mouse lung
To further gain insight into the pathogenesis of these different
viruses and to determine whether differential CCL2 and CSF3
expression levels as described above correlated with the extent of
viral replication, titers in lungs of mice at 1, 3, 4, and 6 dpi were
determined (Fig. 5). Virus replication was detected at 1, 3, and 4 dpi,
but not 6 dpi. Two-way ANOVA revealed that virus titers in lungs of
mice infectedwith the 1918-HA virus were signiﬁcantly different over
the entire time course of the experiment as compared to lungs of mice
infected with 1957-HA, 2009-HA, and NY312 viruses (P=0.008,
P=0.001, and P=0.011, respectively). Nevertheless, a per day post
hoc statistical analysis using t-test only revealed statistically signif-
icant differences between 1918-HA and 2009-HA infected mice at 3
and 4 dpi (P=0.024 and P=0.037, respectively). A comparison of
virus titers between 1918-HA and 1968-HA infected mice revealedthat statistical signiﬁcance was narrowly missed (P=0.065). The only
other signiﬁcant differences detected by 2-way ANOVA analysis were
between mice infected with 1957-HA and 2009-HA (P=0.038) and
between 2009-HA and NY312 infectedmice (P=0.01), indicating that
viral titers in lungs infected with 2009-HA were lower when
compared to NY312 infected lungs. However, a post hoc analysis
using t-test failed to demonstrate signiﬁcant differences in virus titer
between 2009-HA and NY312 infected lungs at individual time points
(data not shown). In general, virus titers between the various viruses
were small, with only 1918-HA growing to slightly higher titer in
mouse lung compared to NY312 as assessed over the entire time
course of the experiment.
Fig. 6. SP-D neutralization assay with wild-type inﬂuenza viruses and chimeric
inﬂuenza viruses expressing the HA genes of different inﬂuenza viruses. Chimeric IAV
expressing the HA of pandemic or seasonal IAV (see Table 1) were tested for their
ability to bind to SP-D using a SP-D neutralization and plaque reduction assay as
described in Material and methods. Data are presented as mean±SD. Two-tailed
P values were calculated with an unpaired t test. (P=0.002).
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In order to evaluate the ability of these chimeric viruses to bind to
SP-D protein in vitro, we carried out hemagglutination inhibition
assays (HAI) as well as plaque reduction neutralization assays (PRN)
using different concentrations of recombinant human SP-D protein
(Table 1 and Fig. 6). Human SP-D protein was used because of its high
homology to mouse SP-D and since both native rodent and human
SP-D exhibit similar antiviral activities against several strains of IAV
(Hartshorn et al., 1996). These assays demonstrated that, while only
62.5 ng/ml of SP-D were sufﬁcient to inhibit agglutination of turkey
red blood cells by NY312 in the HAI assay, none of the pandemic HA
expressing viruses (1918-HA, 1957-HA, 1968-HA, or 2009-HA) was
inhibited from agglutinating turkey erythrocytes even in the presence
of 2 μg/ml of SP-D, the highest amount of SP-D tested (Table 1).
Neutralization of viruses by SP-D
Similarly, PRN assays showed that only 7 ng/ml of SP-D protein
was sufﬁcient to cause 50% inhibition (IC50) in the ability of the
NY312 virus to form plaques in MDCK cells. In contrast, incubation
with the highest concentration of SP-D tested (120 ng/ml) caused no
signiﬁcant reduction in the number of plaques of any of the
pandemic HA expressing viruses (Fig. 6). Taken together, these
data support a hypothesis that low SP-D binding activity of pandemic
HA proteins may contribute to infection of alveolar lining cells,
increased activation of inﬂammatory responses, and more severe
lung pathology.
Discussion
Inﬂuenza A viruses (IAV) have the ability to infect a wide variety of
warm-blooded animal hosts including wild and domestic avian and
mammalian species, as well as humans. In humans, IAV are among the
most common causes of acute respiratory infections and among the
most signiﬁcant because of their high associated morbidity and
mortality (Thompson et al., 2003). In the past 100 years, there were
pandemics in 1918, 1957, 1968, 1977, and 2009 (Taubenberger and
Morens, 2009). In 1918, the worst pandemic in recorded history
caused approximately 546,000 excess deaths (675,000 total deaths)
in the United States (Taubenberger and Morens, 2006) and killed up
to 50 million people worldwide (Johnson and Mueller, 2002). The
1957 and 1968 pandemics caused approximately 70,000 and 34,000
excess deaths in the United States, respectively (Noble, 1982). While
it is too early to assess the full impact of the 2009 pandemic, in its ﬁrst
year, there have been approximately 12,500 deaths in the United
States of which the vast majority have been in individuals under age
65 (CDC, 2010).
IAV infection is initiated by viral attachment mediated by its HA
proteins binding to SA-bearing cell surface receptors (Matrosovich,
Stech, and Klenk, 2009). HA glycoproteins bind to certain SA isomers
on host glycoproteins, strongly supporting a role in determining host
range and likely cell tropism (Matrosovich et al., 2000; Nicholls et al.,
2007; Rogers and Paulson, 1983; Salomon and Webster, 2009;
Taubenberger, 2006). However, several recent studies have demon-
strated that enhanced binding to α2-6 SA is not in itself adequate for
host switch of an avian-adapted IAV to humans nor is it a requirement
for human infections as IAV bearing the 1918 HA with different
receptor binding domain (RBD) conﬁgurations (α2-3, α2-6, and
blended α2-3/α2-6 SA speciﬁcities) were all shown to be virulent in
mice (Qi et al., 2009) and ferrets (Tumpey et al., 2007). Notably
though, viral constructs with the 1918 HA having only α2-3 SA
speciﬁcity did not transmit between ferrets (Tumpey et al., 2007).
Moreover, mice infected with avian viruses with the HA RBDmutated
to exclusively bindα2-6 SA do not show infection of lower respiratory
tract epithelial cells or increased virulence (Qi et al., 2009; Stevenset al., 2006). Thus, a number of fundamental questions about the
signiﬁcance of HA RBD speciﬁcity as it relates to cellular tropism in the
respiratory tract remain unanswered.
Autopsy studies have demonstrated that all IAV pandemics since
1918 have been associated with viral pneumonia and viral replication
in the lower respiratory tract (Gill et al., 2010; Taubenberger and
Morens, 2008). In this study, we explored the hypothesis that SP-D
binding activity would be associated with the ability of pandemic IAV
to replicate in the lower respiratory tract. SP-D has previously been
shown to bind to high mannose type II glycans on some IAV (Crouch,
2000; Hartshorn et al., 1994; Hartshorn et al., 2008). The data
presented here suggest that the HA proteins of pandemic IAV show
signiﬁcantly lower SP-D binding compared to the HA from seasonal
IAVs, which was associated with the ability of these viruses to invade
deeper into the lower lung and infect alveolar lining cells. These
ﬁndings correlate with the in vivo data such that chimeric viruses
expressing the 1918, 1957, 1968, and 2009 pandemic virus HA gene
segments induced more severe disease in mice and enhanced alveolar
and bronchiolar epithelial cell tropism as compared to seasonal IAV.
Pandemic HAs, derived from zoonotic sources, generally have
fewer potential N-linked glycosylation sites, which are observed in
later seasonal IAV strains presumably as a consequence of serial
antigenic drift pressure (Bush et al., 1999; Hensley et al., 2009; Kash
et al., 2010; Wei et al., 2010). More work is needed to correlate
differential glycosylation patterns of the globular head of HA with
pathogenicity and antigenicity. Clearly, the relationship of HA
glycosylation patterns and their pathophysiologic signiﬁcance is
poorly understood. For example, how does the HA glycosylation
pattern of a particular IAV differ in different hosts or particular cell
types? How uniform are the glycans placed at particular N–X–S/T
consensus sites within one virus population or between different IAV
HAs sharing the same site? All available pandemic HAs have low SP-D
binding activity in vitro and are associated with enhanced lower
432 L. Qi et al. / Virology 412 (2011) 426–434respiratory tract tropism in mice, but it is not yet clear whether other
HAs from divergent avian ormammalian IAV that escape SP-D binding
would also cause a similar phenomenon. Indeed, previous reports
suggested that pandemic 1968 H3N2 IAV that was shown to evade
SP-D binding induced more severe disease in mice as compared to IAV
thatwere able to bind to SP-D (Reading et al., 1997; Reading et al., 2009;
Vigerust et al., 2007).Moreover, the latter virusesweremore virulent in
SP-D−/− mice as compared to wild-type mice, demonstrating an
important role of SP-D in IAV pathogenesis (Vigerust et al., 2007).
Elevated expression of inﬂammatory cytokines and chemokines
has been shown to be associated with immunopathogenic responses
to highly virulent inﬂuenza viruses, such as 1918 and H5N1 HPAI
(Kash et al., 2006; Kobasa et al., 2007). Mice infected with chimeric
viruses expressing pandemic HA genes showed marked elevation of
CCL2 and CSF3 compared to the parental NY312 virus whenmeasured
over the whole time course from 1 to 5 dpi. We also observed a
statistically signiﬁcant increased viral replication of the 1918-HA virus
compared to the 1957-HA, 2009-HA, and NY312 viruses that might
partially account for the high CCL2 and CSF3 expression in lungs of
1918-HA infected mice compared to all other viruses. Overall,
however, there was only a weak correlation between cytokine
expression and virus titers. Therefore, the observed pathological
changes among the different viruses were unlikely to be simply
related to the extent of viral replication in the lungs.
However, the fact that CCL2 and CSF3 expression levels were
higher in mice infected with pandemic HA chimeric viruses compared
to NY312 infected mice, and the fact that the major site of replication
in NY312 infected lungs was restricted to the epithelium of the large
airways compared to the bronchiolar and type II alveolar lining cells in
lungs infected with pandemic HA chimeric viruses suggest that cell
tropism, and not whole organ viral load, can inﬂuence inﬂammatory
responses characterized by different chemokine and cytokine expres-
sion proﬁles and inﬁltrating immune cell populations. This hypothesis
is supported by the prevalence of lymphocytes, macrophages and, in
the case of 1918-HA, neutrophils, in the alveolar and interstitial spaces
in the lungs of mice infected with these viruses. Interestingly, we
observed differences in magnitude, duration, and types of inﬂamma-
tory mediators expressed during infection with the different
pandemic HA expressing viruses (Fig. 4 and data not shown).
Infection with virus expressing 1957, 1968, or 2009 pandemic virus
HA resulted in signiﬁcant inﬁltration of macrophages and lympho-
cytes (in agreement with elevated CCL2 expression), whereas in
1918-HA infected mice, we additionally observed a signiﬁcant
inﬁltration of neutrophils (Fig. 3A). While the reason for this
phenomenon is unknown, we observed a correlation between
increased presence of neutrophils and sustained expression of
neutrophil-related chemokines CSF3 and CXCL1 (KC) in lungs of
1918-HA infected mice (Fig. 4 and data not shown). Collectively, our
results suggest that evasion of SP-D binding was associated with
infection of bronchiolar and alveolar epithelial cells, elevated
expression of inﬂammatory cytokines and chemokines, and the
increased inﬁltration of innate immune cells into the lungs of infected
mice. Finally, viruses expressing the 1918 HA were the most virulent
and caused the most severe lung pathology suggesting that the 1918
HA protein contains virulence properties in addition to the evasion of
SP-D binding.
In future work, it will be important to determine the composition
of the glycans of the different HAs examined here to help address
these questions. In a previous study, Qi et al. (2009) demonstrated
that a chimeric NY312 virus expressing an avian-derived H1 HA did
not induce lung pathology even with an α2-6 SA RBD speciﬁcity. It
will also be important to assess SP-D binding and mouse virulence
patterns in avian and swine IAV.
While chimeric viruses expressing the HA of all the available
pandemic IAV all displayed minimal SP-D binding and induced lower
respiratory tract pathology, the 1918 HA was associated with moresevere disease and a unique inﬂammatory cell inﬁltrate dominated by
neutrophils. Thus, while the extent of SP-D binding is a likely
component, it is not the only determinant of pathogenicity of chimeric
pandemic HA viruses and it is clear that individual HA proteins can
affect pathogenicity via multiple, if still poorly deﬁned, mechanisms.
Importantly, as in other recent studies, lung titers alone did not
correlate well with histopathology or outcome (Jagger et al., 2010;
Qi et al., 2009). For example, whereas there was an overall statistical
signiﬁcant difference between virus titers of lungs infected with the
1918-HA virus versus the parental NY312 virus, post hoc analyses did
not reveal signiﬁcant differences at a particular day, indicating that
both viruses replicated to similar titers in mouse lungs. Nevertheless,
the 1918 HA virus induced severe and often lethal disease. Moreover,
the 1918 HA virus showed a unique inﬂammatory inﬁltrate, higher
morbidity and mortality, and the longer duration of disease and the
inﬂammatory response compared to the other pandemic HA viruses
examined, but the mechanisms for this are not yet clear. In summary,
these data reinforce the importance of immunopathology in deter-
mining the outcome of IAV infection and expand our understanding of
inﬂuenza pathogenicity beyond the direct cytopathic effects of viral
replication. This study suggests that reduced SP-D binding could be
associated with the ability of IAV to invade the lower respiratory tract
and to induce severe pathology in otherwise healthy individuals.
Finally, these ﬁndings suggest new avenues for developing new
classes of antiviral drugs that interfere with the ability of IAV to cause
lower respiratory tract pathology.
Materials and methods
Virus preparation and growth
The control IAV, A/New York/312/2001 (H1N1) [NY312], was
produced via reverse genetics as previously described (Qi et al., 2009).
The HA gene segments of A/SouthCarolina/1/1918 (H1N1) (Reid et al.,
1999), A/Japan/305+/1957 (H2N2) (virus kindly supplied by Sue
Epstein at the FDA), A/Hong Kong/1/68 (H3N2), A/Mexico/4108/09
(H1N1) (virus kindly supplied by Heinz Feldmann at the NIH) were
subcloned into the rescue plasmid pHH21 (kindly supplied by
Yoshihiro Kawaoka at the University of Wisconsin at Madison).
Isogenic “1:7” chimeric inﬂuenza viruses containing different HA gene
segments from the viruses described above on the NY312 backbone
were generated as described (Qi et al., 2009). Rescued viruses were
both grown and titers determined by plaque assay in MDCK cells as
previously described (Qi et al., 2009). All rescued viruses had their HA
genes conﬁrmed by comparison with the sequences deposited in
GenBank. Similarly, isogenic “2:6” chimeric viruses using cognate HA
and NA gene segments from the viruses described above on the
NY312 backbone were also generated and sequence veriﬁed.
Ethics statement
All experimental animal work was performed in an enhanced
ABSL3 laboratory at the National Institutes of Heath (NIH) using
animal safety protocols approved by the National Institute of Allergy
and Infectious Diseases Animal Care and Use Committee.
Mouse infection studies
Groups of 8–10 week old female BALB/c mice (Jackson Laborato-
ries, Bar Harbor, ME) were lightly anesthetized in a chamber with
isoﬂurane supplemented with O2 (1.5 L/min) and mice were
intranasally inoculated with 2×105 PFU of inﬂuenza A virus under
enhanced animal BSL3 conditions. Viruses were diluted in sterile
DMEM where appropriate. Body weights were measured daily and
mice were humanely euthanized if they lost more than 25% of their
initial body weight. Lungs from 3 animals were collected at 1, 2, 3, 4,
433L. Qi et al. / Virology 412 (2011) 426–434and 5 dpi for viral titration and cytokine assays for each virus and time
point. Lungs collected for pathology (from 2 mice for each virus at
1–5 dpi) were inﬂated with 10% neutral buffered formalin at time of
isolation to prevent atelectasis. Lung viral titers were determined by
plaque assay (described above) in 10% (wt./vol.) lung suspensions
prepared by homogenization in sterile 1× L-15 media.
Pathology and immunohistochemistry
Mice were humanely euthanized with CO2 and lungs were
removed and inﬂated using 10% formalin. Following ﬁxation for at
least 24 h in 10% formalin, lungs were dehydrated, embedded in
parafﬁn, and 5 μm sections on positively charged slides were either
stained with hematoxylin and eosin for histopathologic examination
(American HistoLabs, Gaithersburg, MD) or were processed for
immunohistochemistry as previously described (Memoli et al.,
2009; Qi et al., 2009). Brieﬂy, tissue sections were dewaxed,
rehydrated, and blocked with methanol/hydrogen peroxide followed
by a heat induced epitope retrieval (HIER) procedure using citrate
buffer, pH 6.0. The samples were then rinsed in PBS, serum blocked,
and incubated with goat anti-inﬂuenza A (Abcam, Inc., Cambridge,
MA; #ab20841) and stained with horse anti-goat-peroxidase (Vector
Laboratories, Burlingame, CA; #PI-9500). The samples were reacted
with diaminobenzidine (DAB), counterstained with hematoxylin,
rinsed, and coverslipped. Lung sections were given a histopathology
severity score as follows: 0, no signiﬁcant pathological changes; 1+,
mild pathological changes; 2+, moderate pathological changes; 3+,
moderately severe pathological changes; 4+, severe pathological
changes. Pathological changes included in the severity scale were
degree and extent of bronchiolitis, alveolitis, inﬂammatory inﬁl-
trates, pulmonary edema, and hemorrhage.
Determination of cytokine and chemokine protein levels
A mouse multiplex Ab bead kit (Bio-Plex Pro Mouse Cytokine
23-plex Assay; Bio-Rad Laboratories, Hercules, CA) was used to
measure chemokine and cytokine secretion from infected mice lung
tissue. The method allows simultaneous evaluation of murine
cytokines, chemokines, and growth factors. The multiplexed assay
was performed according to the manufacturer's instructions. To
generate a standard curve, 2-fold serial dilutions of appropriate
standards were prepared in L-15 medium. Standards and supernatant
samples were pipetted at 50 μl/well and mixed with 50 μl of the bead
mixture. After a 30 min incubation, wells were washed 3 times with
washing buffer using a vacuum manifold. Detection antibodies were
added for 30 min, the wells were washed 3 times, PE-conjugated
secondary antibody was added for 10 min, the wells were washed 3
times, and samples were analyzed using the Bio-Plex suspension array
system (Bio-Rad). One hundred beads were counted for each analyte
per well and values (pg/g) were calculated.
Determination of SP-D binding by hemagglutination inhibition
(HAI) assay
Recombinant human SP-D protein (112.5 μg/ml) was prepared as
previously described (Brown-Augsburger et al., 1996; Doss et al.,
2009). SP-D protein (at 2 μg/ml) was serially diluted in D-PBS
(containing Ca2+ and Mg2+) (Quality Biological, Inc., Gaithersburg,
MD) in 96 well plates with V-shaped bottoms (Costar). After adding
an equal volume (25 μl) of virus at a ﬁnal concentration of 4 HA units/
well, the virus and SP-D mixture was incubated for 15 min at room
temperature followed by addition of 50 μl of a 0.5% turkey erythrocyte
suspension (Lampire Biological Laboratories, Inc., Pipersville, PA). The
minimum concentration of protein required to inhibit fully the
hemagglutinating activity of the viral suspension was determined
by noting the highest dilution of protein that still inhibitedhemagglutination. Inhibition of HA activity in a given well was
demonstrated by presence of an erythrocyte pellet. If no inhibition of
HA activity was observed at the highest protein concentration used,
then the value was expressed as greater than the maximal protein
concentration tested.
Determination of SP-D binding by plaque reduction neutralization
(PRN) assay
MDCK cells were seeded into 24 well plates and grown to
conﬂuency. SP-D protein (240 ng/ml) was sequentially diluted two-
fold in D-PBS (up to 15 ng/ml) and each dilution was mixed with an
equal volume of virus corresponding to 20–30 plaques per well.
Following pre-incubation at room temperature for 45–60 min, the
mixed samples (100 μl) were layered onto the MDCK cells. Each
samplewas tested in triplicatewells. Virus alonewithout SP-D protein
was included as a control. After incubation at 37 C for 1 h, samples
were aspirated, wells were washed with PBS, and cells were overlaid
with 2% agar (wt./vol.) in 2× DMEM. Plaques were visualized using
crystal violet 48 h later using standard protocols (Cottey et al., 2003).
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